TABLE 3.
Associations of antiplatelet drug use with risk of invasive breast cancer, stratified by age at index date
| Age < 55 years | Age ≥ 55 and <70 years | Age ≥ 70 years | p heterogeneity | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n cases | n controls | OR (95% CI) a | n cases | n controls | OR (95% CI) a | n cases | n controls | OR (95% CI) a | ||
| Low‐dose aspirin | ||||||||||
| Use categories | ||||||||||
| Never use | 19 788 | 197 360 | 1.00 (ref.) | 27 448 | 274 983 | 1.00 (ref.) | 13 032 | 131 020 | 1.00 (ref.) | |
| Ever use | 401 | 4530 | 0.95 (0.85‐1.07) | 3228 | 31 777 | 0.98 (0.94‐1.03) | 4919 | 48 490 | 1.00 (0.96‐1.05) | .64 |
| Long‐term use | 130 | 1765 | 0.81 (0.66‐0.99) | 1816 | 17 714 | 0.99 (0.93‐1.05) | 3240 | 31 388 | 1.02 (0.97‐1.07) | .05 |
| Cumulative DDDs | ||||||||||
| Never use | 19 788 | 197 360 | 1.00 (ref.) | 27 448 | 274 983 | 1.00 (ref.) | 13 032 | 131 020 | 1.00 (ref.) | |
| <500 | 181 | 1816 | 1.04 (0.89‐1.22) | 765 | 7600 | 0.97 (0.90‐1.05) | 876 | 8479 | 1.02 (0.94‐1.09) | |
| ≥500 to <1000 | 90 | 949 | 1.02 (0.82‐1.28) | 647 | 6463 | 0.97 (0.89‐1.05) | 803 | 8623 | 0.92 (0.85‐0.99) | |
| ≥1000 to <2000 | 80 | 1029 | 0.84 (0.66‐1.07) | 849 | 8311 | 0.99 (0.92‐1.07) | 1268 | 12 445 | 1.01 (0.95‐1.08) | |
| ≥2000 to <3000 | 29 | 471 | 0.67 (0.46‐0.99) | 504 | 4979 | 0.98 (0.89‐1.08) | 904 | 8596 | 1.05 (0.97‐1.13) | |
| ≥3000 | 21 | 265 | 0.85 (0.54‐1.33) | 463 | 4424 | 1.01 (0.91‐1.12) | 1068 | 10 347 | 1.04 (0.97‐1.12) | |
| OR per 1000 DDDs | 401 | 4530 | 0.92 (0.84‐1.00) | 3228 | 31 777 | 1.00 (0.98‐1.02) | 4919 | 48 490 | 1.01 (0.99‐1.03) | |
| Clopidogrel | ||||||||||
| Use categories | ||||||||||
| Never use | 20 120 | 201 096 | 1.00 (ref.) | 30 285 | 302 584 | 1.00 (ref.) | 17 332 | 172 717 | 1.00 (ref.) | |
| Ever use | 69 | 794 | 1.00 (0.75‐1.32) | 391 | 4176 | 0.95 (0.85–1.07) | 619 | 6793 | 0.92 (0.83‐1.01) | .80 |
| Long‐term use | 18 | 166 | 1.28 (0.77‐2.12) | 107 | 982 | 1.07 (0.87‐1.32) | 162 | 1833 | 0.88 (0.75‐1.05) | .24 |
| Cumulative DDDs | ||||||||||
| Never use | 20 120 | 201 096 | 1.00 (ref.) | 30 285 | 302 584 | 1.00 (ref.) | 17 332 | 172 717 | 1.00 (ref.) | |
| <500 | 42 | 459 | 1.07 (0.75‐1.51) | 191 | 2321 | 0.85 (0.73‐1.00) | 300 | 3446 | 0.87 (0.77‐0.99) | |
| ≥500 to <1000 | 9 | 169 | 0.60 (0.30‐1.18) | 93 | 873 | 1.06 (0.85‐1.32) | 157 | 1514 | 1.04 (0.88‐1.24) | |
| ≥1000 to <2000 | 17 | 110 | 1.74 (1.03‐2.96) | 72 | 683 | 1.03 (0.80–1.32) | 107 | 1154 | 0.94 (0.76‐1.15) | |
| ≥2000 to <3000 | < 5 | 39 | (−) | 23 | 166 | 1.37 (0.88‐2.13) | 36 | 394 | 0.92 (0.65‐1.31) | |
| ≥3000 | < 5 | 17 | (−) | 12 | 133 | 0.89 (0.49‐1.61) | 19 | 285 | 0.67 (0.42‐1.06) | |
| OR per 1000 DDDs | 69 | 794 | 0.89 (0.66‐1.18) | 391 | 4176 | 1.03 (0.94‐1.13) | 619 | 6793 | 0.95 (0.88‐1.02) | |
| Dipyridamole | ||||||||||
| Use categories | ||||||||||
| Never use | 20 141 | 201 316 | 1.00 (ref.) | 30 287 | 303 094 | 1.00 (ref.) | 17 364 | 173 536 | 1.00 (ref.) | |
| Ever use | 48 | 574 | 0.86 (0.62‐1.19) | 389 | 3666 | 1.03 (0.91‐1.17) | 587 | 5974 | 1.02 (0.93‐1.13) | .52 |
| Long‐term use | 12 | 226 | 0.51 (0.28‐0.94) | 209 | 1891 | 1.08 (0.92‐1.28) | 306 | 3088 | 1.05 (0.92‐1.19) | .005 |
| Cumulative DDDs | ||||||||||
| Never use | 20 141 | 201 316 | 1.00 (ref.) | 30 287 | 303 094 | 1.00 (ref.) | 17 364 | 173 536 | 1.00 (ref.) | |
| <500 | 26 | 222 | 1.20 (0.79‐1.84) | 115 | 1132 | 0.98 (0.80‐1.19) | 175 | 1850 | 0.97 (0.82‐1.14) | |
| ≥500 to <1000 | 10 | 126 | 0.82 (0.42‐1.58) | 65 | 643 | 1.00 (0.77–1.31) | 106 | 1036 | 1.07 (0.87‐1.31) | |
| ≥1000 to <2000 | 9 | 125 | 0.72 (0.36‐1.45) | 105 | 897 | 1.15 (0.93‐1.42) | 136 | 1433 | 1.00 (0.83‐1.20) | |
| ≥2000 to <3000 | < 5 | 73 | (−) | 55 | 566 | 0.94 (0.71‐1.25) | 87 | 892 | 1.03 (0.82‐1.29) | |
| ≥3000 | < 5 | 28 | (−) | 49 | 428 | 1.13 (0.83‐1.53) | 83 | 763 | 1.17 (0.92‐1.48) | |
| OR per 1000 DDDs | 48 | 574 | 0.71 (0.53–0.95) | 389 | 3666 | 1.03 (0.97‐1.10) | 587 | 5974 | 1.03 (0.98‐1.08) | |
Abbreviations: CI, confidence interval; DDD, defined daily dose; OR, Odds ratio.
a
Adjusted for age, calendar time (by risk‐set matching and the conditional analysis) and and covariates listed in the Data S3.